Evidence map›Paper›PMID 26559377›Full record

ArticleThe American journal of surgical pathology2015

A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas.

Olca Basturk, Seung-Mo Hong, Laura D Wood, N Volkan Adsay, Jorge Albores-Saavedra, Andrew V Biankin, Lodewijk A A Brosens, Noriyoshi Fukushima, Michael Goggins, Ralph H Hruban and 14 more

Registry-linked trialOpen access · greenAbstract readConsensus Statement
In one paragraph

Article in The American journal of surgical pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05495685 (Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood), which is not on this map. Cited by 389 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
389citing papers in PubMed, 2 pooled it
24.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05495685 unknown statusnot on this mapstarted 2022, after this paper: background citation

Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study

TypeobservationalSponsorChanghai HospitalRan2022 to 2024Enrolled450ConditionsCancer
3 · Its place in the literature

Who cites it

389 citing papers in PubMed, 2 syntheses or guidelines pooled it, 821 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. High grade PanIN is associated with malignancy risk in IPMN patients.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

329 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 6 countries.

Olca Basturk*Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY ‡Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD §Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, GA §§Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH †Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, Korea ∥Department of Pathology, Medica Sur Clinic and Foundation, Mexico City, Mexico ¶Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, UK #Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands **Department of Pathology, Jichi Medical University, Shimotsuke ††Department of Pathology, Cancer Institute, Japanese Foundation for Cancer Research ¶¶Department of Pathology, Hakujikai Memorial Hospital †††Division of Cancer Genomics, National Cancer Center Research Institute §§§Institute for Integrated Medical Sciences, Tokyo Women's Medical University, Tokyo ##Department of Surgery, Kyoto University, Kyoto, Japan ‡‡Department of Pathology, Technical University Munich, Munich ∥∥Department of General, Visceral, Thoracic and Vascular Surgery, University of Bonn, Bonn ‡‡‡Institute of Pathology, Heinrich-Heine University and University Hospital of Düsseldorf, Düsseldorf, Germany ***Service d'Anatomie Pathologique, Hôpital Cochin, Paris, France.
Seung-Mo Hong
Laura D Wood
N Volkan Adsay
Jorge Albores-Saavedra
Andrew V Biankin
Lodewijk A A Brosens
Noriyoshi Fukushima
Michael Goggins
Ralph H Hruban
Yo Kato
David S Klimstra
Günter Klöppel
Alyssa Krasinskas
Daniel S Longnecker
Hanno Matthaei
G Johan A Offerhaus
Michio Shimizu
Kyoichi Takaori
Benoit Terris
Shinichi Yachida
Irene Esposito
Toru Furukawa
Baltimore Consensus Meeting
Johns Hopkins University · USEmory University Hospital · USMemorial Sloan Kettering Cancer Center · USUlsan College · KRUniversity Medical Center Utrecht · NLHospital Médica Sur · MXUniversity of Glasgow · GB

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
Cancer Research UK 17263NCI NIH HHS P50 CA062924NCI NIH HHS P50 CA62924Wellcome Trust 103721
6 · The paper itself

Abstract

International experts met to discuss recent advances and to revise the 2004 recommendations for assessing and reporting precursor lesions to invasive carcinomas of the pancreas, including pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN), mucinous cystic neoplasm, and other lesions. Consensus recommendations include the following: (1) To improve concordance and to align with practical consequences, a 2-tiered system (low vs. high grade) is proposed for all precursor lesions, with the provision that the current PanIN-2 and neoplasms with intermediate-grade dysplasia now be categorized as low grade. Thus, "high-grade dysplasia" is to be reserved for only the uppermost end of the spectrum ("carcinoma in situ"-type lesions). (2) Current data indicate that PanIN of any grade at a margin of a resected pancreas with invasive carcinoma does not have prognostic implications; the clinical significance of dysplasia at a margin in a resected pancreas with IPMN lacking invasive carcinoma remains to be determined. (3) Intraductal lesions 0.5 to 1 cm can be either large PanINs or small IPMNs. The term "incipient IPMN" should be reserved for lesions in this size with intestinal or oncocytic papillae or GNAS mutations. (4) Measurement of the distance between an IPMN and invasive carcinoma and sampling of intervening tissue are recommended to assess concomitant versus associated status. Conceptually, concomitant invasive carcinoma (in contrast with the "associated" group) ought to be genetically distinct from an IPMN elsewhere in the gland. (5) "Intraductal spread of invasive carcinoma" (aka, "colonization") is recommended to describe lesions of invasive carcinoma invading back into and extending along the ductal system, which may morphologically mimic high-grade PanIN or even IPMN. (6) "Simple mucinous cyst" is recommended to describe cysts >1 cm having gastric-type flat mucinous lining at most minimal atypia without ovarian-type stroma to distinguish them from IPMN. (7) Human lesions resembling the acinar to ductal metaplasia and atypical flat lesions of genetically engineered mouse models exist and may reflect an alternate pathway of carcinogenesis; however, their biological significance requires further study. These revised recommendations are expected to improve our management and understanding of precursor lesions in the pancreas.

Indexed as

Terminology as TopicBiopsyCarcinoma in SituCarcinoma, Pancreatic DuctalConsensusCooperative BehaviorHumansInternational CooperationNeoplasm GradingNeoplasm InvasivenessNeoplasms, Cystic, Mucinous, and SerousPancreatic NeoplasmsPrecancerous ConditionsPredictive Value of TestsTumor Burden

Identifiers

PMID26559377
PMCPMC4646710
OpenAlexW2431396139

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.